<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10755397</article-id><article-id pub-id-type="pmc">2374495</article-id><article-id pub-id-type="pii">6691087</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.1087</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Riccardi</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mora</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tinelli</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Valentini</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brugnatelli</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Spanedda</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>De Paoli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barbarano</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Di Stasi</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Giordano</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Delfini</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nicoletti</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bergonzi</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Rinaldi</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Piccinini</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Ascari</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab>for the Co-operative Group of study and Treatment of Multiple Myeloma</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Medicina Interna e Oncologia Medica, <label>2</label>Direzione Scientifica, Universit&#x000e0; and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, 27100</aff><aff id="aff3"><label>3</label>Istituto di Ematologia, Universit&#x000e0; di Ferrara, Ferrara, 44100</aff><aff id="aff4"><label>4</label>Divisione di Medicina II, Ospedale di Legnano, Legnano, 20025</aff><aff id="aff5"><label>5</label>Divisione di Ematologia, Ospedale di Niguarda, Milano, 20100</aff><aff id="aff6"><label>6</label>Divisione di Medicina I, Ospedale di Piacenza, Piacenza, 29100</aff><aff id="aff7"><label>7</label>Servizio di Oncologia, Ospedale S Anna, Como, 22100</aff><aff id="aff8"><label>8</label>Divisione di Ematologia, Ospedale di Pesaro, Pesaro, 61100</aff><aff id="aff9"><label>9</label>Semeiotica Medica, Universit&#x000e0; Cattolica di Roma, Roma, 00168</aff><aff id="aff10"><label>10</label>Divisione di Medicina II, Ospedale di Cremona, Cremona, 26100</aff><aff id="aff11"><label>11</label>Divisione di Medicina I, Ospedale di Magenta, Magenta, 20013</aff><aff id="aff12"><label>12</label>Istituto di Oncologia, Universit&#x000e0; di Modena, Modena, 41100, Italy</aff><pub-date pub-type="epub"><day>06</day><month>03</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>04</month><year>2000</year></pub-date><volume>82</volume><issue>7</issue><fpage>1254</fpage><lpage>1260</lpage><history><date date-type="received"><day>22</day><month>03</month><year>1999</year></date><date date-type="rev-recd"><day>06</day><month>10</month><year>1999</year></date><date date-type="accepted"><day>04</day><month>11</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95&#x00025; confidence interval 0.57&#x02013;2.42;<italic>P</italic> = 0.64). Disease progression occurred within a year in about 50&#x00025; of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, <italic>P</italic> = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs &#x0003e; 92 months;<italic>P</italic> = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>multiple myeloma</kwd><kwd>stage I</kwd><kwd>early or delayed treatment</kwd><kwd>survival</kwd></kwd-group></article-meta></front></article>


